Screener
Vaxcyte, Inc. PCVX EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Vaxcyte, Inc.’s reported figures.
The source filing: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026. Open the filing →
- Filed
- May 6, 2026, 4:12 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001649094-26-000017
FAQ
- What is Vaxcyte, Inc.'s EBITDA?
- Vaxcyte, Inc. (PCVX) reported EBITDA of -$342.9M in Q1 2026.
- How has Vaxcyte, Inc.'s EBITDA changed year-over-year?
- Vaxcyte, Inc.'s EBITDA decreased by 92.8% year-over-year, from -$177.84M to -$342.9M.
- What is the long-term trend for Vaxcyte, Inc.'s EBITDA?
- Over 4 years (2021 to 2025), Vaxcyte, Inc.'s EBITDA has grown at a 72.8% compound annual growth rate (CAGR), from -$101.87M to -$907.28M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Vaxcyte, Inc.'s ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude